A high resolution genomic portrait of bladder cancer: Correlation between genomic aberrations and the DNA damage response

Oncogene

Volumn 32, Issue 31, 2013, Pages 3577-3586

  Schepeler, T ^a   Lamy, P ^a   Hvidberg, V ^a   Laurberg, J R ^a   Fristrup, N ^a   Reinert, T ^a   Bartkova, J ^b   Tropia, L ^c   Bartek, J ^b,d   Halazonetis, T D ^c   Pan, C C ^e   Borre, M ^a   Dyrskjot L ^a   Orntoft T F ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

bladder cancer; DNA damage response; SNP array; Timeless

Indexed keywords

ATM PROTEIN; DNA; FIBROBLAST GROWTH FACTOR RECEPTOR 3; HISTONE H2AX; PROTEIN P53;

ARTICLE; ATAXIA TELANGIECTASIA; BLADDER CANCER; CANCER RESEARCH; CANCER RISK; CHROMOSOME ABERRATION; COHORT ANALYSIS; COPY NUMBER VARIATION; DNA DAMAGE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOMIC ABERRATION; GENOMIC INSTABILITY; GENOMICS; HUMAN; IN VITRO STUDY; LOG RANK TEST; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE MICROARRAY; UNIPARENTAL DISOMY;

ADULT; AGED; AGED, 80 AND OVER; CARRIER PROTEINS; CELL CYCLE PROTEINS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DISEASE PROGRESSION; DNA DAMAGE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HOMOZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UNIPARENTAL DISOMY; URINARY BLADDER NEOPLASMS;

ATAXIA TELANGIECTASIA;

EID: 84881238011     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.381     Document Type: Article

References (56)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 2005; 5: 713-725.
3. Lindgren D, Frigyesi A, Gudjonsson S, Sjodahl G, Hallden C, Chebil G et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010; 70: 3463-3472.
4. Blaveri E, Brewer JL, Roydasgupta R, Fridlyand J, DeVries S, Koppie T et al. Bladder cancer stage and outcome by array-based comparative genomic hybridization. Clin Cancer Res 2005; 11: 7012-7022.
5. Zieger K, Marcussen N, Borre M, Orntoft TF, Dyrskjot L. Consistent genomic alterations in carcinoma in situ of the urinary bladder confirm the presence of two major pathways in bladder cancer development. Int J Cancer 2009; 125: 2095-2103.
6. Zieger K, Wiuf C, Jensen KM, Orntoft TF, Dyrskjot L. Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer. BMC Cancer 2009; 9: 149.
7. Koed K, Wiuf C, Christensen LL, Wikman FP, Zieger K, Moller K et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 2005; 65: 34-45.
8. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434: 864-870.
9. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency'. Cell Cycle 2007; 6: 2344-2347.
10. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434: 907-913.
11. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010; 11: 220-228.
12. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008; 319: 1352-1355.
13. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009; 461: 1071-1078.
14. Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40: 179-204.
15. Chou DM, Elledge SJ. Tipin and Timeless form a mutually protective complex required for genotoxic stress resistance and checkpoint function. Proc Natl Acad Sci USA 2006; 103: 18143-18147.
16. Yoshizawa-Sugata N, Masai H. Human Tim/Timeless-interacting protein, Tipin, is required for efficient progression of S phase and DNA replication checkpoint. J Biol Chem 2007; 282: 2729-2740.
17. McFarlane RJ, Mian S, Dalgaard JZ. The many facets of the Tim-Tipin protein families' roles in chromosome biology. Cell Cycle 2010; 9: 700-705.
18. Wu Q, Hoffmann MJ, Hartmann FH, Schulz WA. Amplification and overexpression of the ID4 gene at 6p22.3 in bladder cancer. Mol Cancer 2005; 4: 16.
19. Santarius T, Bignell GR, Greenman CD, Widaa S, Chen L, Mahoney CL et al. GLO1-A novel amplified gene in human cancer. Genes Chromosomes Cancer 2010; 49: 711-725.
20. Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011; 144: 27-40.
21. Langbein S, Szakacs O, Wilhelm M, Sukosd F, Weber S, Jauch A et al. Alteration of the LRP1B gene region is associated with high grade of urothelial cancer. Lab Invest 2002; 82: 639-643.
22. Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K et al. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci USA 2010; 107: 15145-15150.
23. Dereli-Oz A, Versini G, Halazonetis TD. Studies of genomic copy number changes in human cancers reveal signatures of DNA replication stress. Mol Oncol 2011; 5: 308-314.
24. Le Tallec B, Dutrillaux B, Lachages AM, Millot GA, Brison O, Debatisse M. Molecular profiling of common fragile sites in human fibroblasts. Nat Struct Mol Biol 2011; 18: 1421-1423.
25. Letessier A, Millot GA, Koundrioukoff S, Lachages AM, Vogt N, Hansen RS et al. Cell-type-specific replication initiation programs set fragility of the FRA3B fragile site. Nature 2011; 470: 120-123.
26. Lapunzina P, Monk D. The consequences of uniparental disomy and copy number neutral loss-of-heterozygosity during human development and cancer. Biol Cell 2011; 103: 303-317.
27. Vetter G, Saumet A, Moes M, Vallar L, Le Bechec A, Laurini C et al. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene 2010; 29: 4436-4448.
28. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM et al. Signatures of mutation and selection in the cancer genome. Nature 2010; 463: 893-898.
29. Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE. Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol 2004; 171: 419-425.
30. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. Oncogeneinduced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444: 633-637.
31. Takacova S, Slany R, Bartkova J, Stranecky V, Dolezel P, Luzna P et al. DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo. Cancer cell 2012; 21: 517-531.
32. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432: 316-323.
33. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, Zhang Z et al. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. Clin Cancer Res 2002; 8: 171-179.
34. Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol 2010; 2: a001008.
35. Gotter AL, Suppa C, Emanuel BS. Mammalian TIMELESS and Tipin are evolutionarily conserved replication fork-associated factors. J Mol Biol 2007; 366: 36-52.
36. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011; 17: 5582-5592.
37. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006; 49: 466-477.
38. Weaver BA, Silk AD, Montagna C, Verdier-Pinard P, Cleveland DW. Aneuploidy acts both oncogenically and as a tumor suppressor. Cancer Cell 2007; 11: 25-36.
39. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011; 18: 721-727.
40. Martin SA, Hewish M, Lord CJ, Ashworth A. Genomic instability and the selection of treatments for cancer. J Pathol 2010; 220: 281-289.
41. Lord CJ, Ashworth A. The DNA damage response and cancer therapy. Nature 2012; 481: 287-294.
42. Tuna M, Knuutila S, Mills GB. Uniparental disomy in cancer. Trends Mol Med 2009; 15: 120-128.
43. Mullighan CG, Goorha S, Radtke I, Miller CB, Coustan-Smith E, Dalton JD et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
44. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C et al. Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 2007; 117: 314-325.
45. Hafner C, Knuechel R, Stoehr R, Hartmann A. Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies. Int J Cancer 2002; 101: 1-6.
46. Dheekollu J, Wiedmer A, Hayden J, Speicher D, Gotter AL, Yen T et al. Timeless links replication termination to mitotic kinase activation. PLoS One 2011; 6: e19596.
47. Yang X, Wood PA, Hrushesky WJ. Mammalian TIMELESS is required for ATMdependent CHK2 activation and G2/M checkpoint control. J Biol Chem 2010; 285: 3030-3034.
48. Unsal-Kacmaz K, Chastain PD, Qu PP, Minoo P, Cordeiro-Stone M, Sancar A et al. The human Tim/Tipin complex coordinates an intra-S checkpoint response to UV that slows replication fork displacement. Mol Cell Biol 2007; 27: 3131-3142.
49. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol 2005; 25: 3109-3116.
50. Smith-Roe SL, Patel SS, Simpson DA, Zhou YC, Rao S, Ibrahim JG et al. Timeless functions independently of the Tim-Tipin complex to promote sister chromatid cohesion in normal human fibroblasts. Cell Cycle 2011; 10: 1618-1624.
51. Fu A, Leaderer D, Zheng T, Hoffman AE, Stevens RG, Zhu Y. Genetic and epigenetic associations of circadian gene TIMELESS and breast cancer risk. Mol Carcinog (e-pub ahead of print 17 October 2011; doi:10.1002/mc.20862).
52. Aly A, Ganesan S. BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol 2011; 3: 66-74.
53. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17: 688-695.
54. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 2010; 5: e13821.
55. Schepeler T, Mansilla F, Christensen LL, Orntoft TF, Andersen CL. Clusterin expression can be modulated by changes in TCF1-mediated Wnt signaling. J Mol Signal 2007; 2: 6.
56. Robinson JT, Thorvaldsdottir H, Winckler W, Guttman M, Lander ES, Getz G et al. Integrative genomics viewer. Nat Biotechnol 2011; 29: 24-26.